Compare AUDC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUDC | OBIO |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.9M | 240.7M |
| IPO Year | 2000 | 2020 |
| Metric | AUDC | OBIO |
|---|---|---|
| Price | $9.07 | $3.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.50 | ★ $14.25 |
| AVG Volume (30 Days) | 121.9K | ★ 213.9K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | $4.24 | N/A |
| Revenue Next Year | $2.18 | $12.43 |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $6.95 | $2.20 |
| 52 Week High | $11.48 | $5.42 |
| Indicator | AUDC | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 46.70 |
| Support Level | $8.71 | $3.77 |
| Resistance Level | $9.82 | $4.18 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 11.48 | 37.50 |
AudioCodes Ltd provides voice communications solutions for enterprises, contact centers, and service providers, including voice infrastructure, cloud-based platforms, and Voice AI applications. Its AudioCodes Live Platform is a cloud-based service delivery platform that enables provisioning, management, and operation of voice and AI-based communication services, including PSTN connectivity and integration with platforms such as Microsoft Teams, Webex Calling, and Zoom Phone. The company's solutions are organized into three layers: voice infrastructure and devices, cloud-based platforms, and Voice AI applications for contact center and productivity use cases. It also offers management tools such as One Voice Operations Center (OVOC), Device Manager, and AudioCodes Routing Manager (ARM).
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.